TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28951368

Group type: EXPERIMENTAL
Intervention: Colorectal LSTs
Number of subjects: 52

Group type: COMPARATOR
Intervention: LST‐NG‐PD
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: LSTs
Number of subjects: 52
Study: 26209535

Group type: EXPERIMENTAL
Intervention: Daily low-dose hCG (125 IU) for luteal phase support after GnRHa trigger, initiated on stimulation day 2 or day 6.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group followed a standard antagonist protocol without hCG supplementation.
Number of subjects: 93
Study: 24021360

Group type: EXPERIMENTAL
Intervention: internet-based CBT (iCBT)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study: 19939650

Group type: EXPERIMENTAL
Intervention: Enriched dairy product (0.6 L/day) for 5 months
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard whole milk (0.6 L/day) for 5 months
Number of subjects: 107
Study: 19729323

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 300 mg day(-1) for 15 days (Group III)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (non-varicose veins from healthy patients, Group I)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Varicose veins (Group II, no drug treatment)
Number of subjects: 2
Study: 17825692

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 880 microg IN qSh for 10 doses
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fluticasone furoate 250 microg IV
Number of subjects: 16
Study: 15145921

Group type: EXPERIMENTAL
Intervention: Creatinine standardization
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Muscle mass accounting
Number of subjects: 229
Study: 11260238

Group type: EXPERIMENTAL
Intervention: 10% diethylenetriaminepentaacetic acid (DTPA) cream
Number of subjects: 28
Study: 9027670

Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 8312583

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (reducing fat intake to 15-20% of total calories)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Tamoxifen adjuvant therapy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention (in patients not receiving tamoxifen)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Tamoxifen without dietary intervention
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: Dietary control group
Number of subjects: 93
Study: 3520317

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 36
Study: 31034447

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (FHL, 20 U; GL, 20 U)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 391

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 391
Study: 28682184

Group type: EXPERIMENTAL
Intervention: Theory-based multimedia software (self-taught DVD-Rom)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 130
Study: 26928567

Group type: EXPERIMENTAL
Intervention: 200mg/kg of poractant alfa (surfactant)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 118
Study: 25005327

Group type: EXPERIMENTAL
Intervention: golimumab 50 mg + MTX
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg + MTX
Number of subjects: 478

Group type: COMPARATOR
Intervention: placebo + MTX
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: golimumab + MTX
Number of subjects: 478
Study: 23252007

Group type: EXPERIMENTAL
Intervention: Intravenous hydration before and after coronary angiography or angioplasty (Group A, n=40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Oral tap water before and after the procedures (Group B, n=40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Postprocedural drinking water only (Group C, n=40)
Number of subjects: 120
Study: 20422945

Group type: EXPERIMENTAL
Intervention: Test formulation of 50 mg itopride HCl
Number of subjects: 28

Group type: COMPARATOR
Intervention: Reference formulation of 50 mg itopride HCl
Number of subjects: 28
Study: 18249288

Group type: EXPERIMENTAL
Intervention: ClearSmile appliances (TAs)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Light force (25 g)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Heavy force (225 g)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no force)
Number of subjects: 27
Study: 16182830

Group type: EXPERIMENTAL
Intervention: ganciclovir
Number of subjects: 205

Group type: COMPARATOR
Intervention: no prophylaxis
Number of subjects: 205

Group type: COMPARATOR
Intervention: acyclovir
Number of subjects: 205

Group type: COMPARATOR
Intervention: D-/R- group
Number of subjects: 205

Group type: COMPARATOR
Intervention: D-/R+ group
Number of subjects: 205

Group type: COMPARATOR
Intervention: D+/R+ group
Number of subjects: 205

Group type: COMPARATOR
Intervention: D+/R- group
Number of subjects: 205

Group type: COMPARATOR
Intervention: without ganciclovir prophylaxis
Number of subjects: 205

Group type: COMPARATOR
Intervention: with infection
Number of subjects: 205
Study: 12817109

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 11187583

Group type: EXPERIMENTAL
Intervention: In-patient treatment
Number of subjects: 6

Group type: COMPARATOR
Intervention: Out-patient treatment
Number of subjects: 6
Study: 8936350

Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg orally three times daily for 2 years)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (three times daily for 2 years)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acyclovir (in subgroup with disease duration of at least 2 years)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (in subgroup with disease duration of at least 2 years)
Number of subjects: 60
Study: 1397668

Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 3887100

Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (5 mg/d)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 31079600

Group type: EXPERIMENTAL
Intervention: cilostazol SR (Pletaal SR Cap.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: cilostazol CR (Cilostan CR Tab.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: cilostazol SR
Number of subjects: 30
Study: 28251920

Group type: EXPERIMENTAL
Intervention: Remote nonpainful electrical upper arm skin stimulation (200-μs, 150-μs, and 100-μs pulse width stimuli)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Remote nonpainful electrical upper arm skin stimulation (200-μs stimulation protocol)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Remote nonpainful electrical upper arm skin stimulation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Sham stimuli
Number of subjects: 71
Study: 25239965

Group type: EXPERIMENTAL
Intervention: Inspectorate's supervision programme (A)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Assessment with a questionnaire (B)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Site visit assessment (C)
Number of subjects: 233
Study: 22008097

Group type: EXPERIMENTAL
Intervention: Symphyseal donor defects filled with bone substitute
Number of subjects: 26

Group type: COMPARATOR
Intervention: Unfilled symphyseal donor defects
Number of subjects: 26
Study: 21799772

Group type: EXPERIMENTAL
Intervention: Polyantigenic whole cell lysate (WCL)
Number of subjects: 979

Group type: COMPARATOR
Intervention: No detectable baseline IFN-γ responses
Number of subjects: 979

Group type: COMPARATOR
Intervention: 0 baseline IFN-γ responses
Number of subjects: 979

Group type: COMPARATOR
Intervention: 1 baseline IFN-γ response
Number of subjects: 979

Group type: COMPARATOR
Intervention: 2 baseline IFN-γ responses
Number of subjects: 979

Group type: COMPARATOR
Intervention: 3 baseline IFN-γ responses
Number of subjects: 979

Group type: EXPERIMENTAL
Intervention: Each increment in the number of detectable baseline IFN-γ responses
Number of subjects: 979
Study: 19489942

Group type: EXPERIMENTAL
Intervention: bosentan
Number of subjects: 14

Group type: COMPARATOR
Intervention: healthy controls
Number of subjects: 14
Study: 16757445

Group type: EXPERIMENTAL
Intervention: Internet group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Face-to-face group
Number of subjects: 40
Study: 15557943

Group type: EXPERIMENTAL
Intervention: Sedation with midazolam and placebo pharyngeal spray (midazolam group)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Placebo sedation and lidocaine pharyngeal spray (lidocaine group)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo sedation and placebo pharyngeal spray (placebo group)
Number of subjects: 252

Group type: COMPARATOR
Intervention: No intravenous cannula/pharyngeal spray (control group)
Number of subjects: 252
Study: 11232742

Group type: EXPERIMENTAL
Intervention: Modified digital inclinometer
Number of subjects: 39
Study: 9275135

Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium (0.5 mg) plus salbutamol (2.5 mg) (Combivent)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Nebulized salbutamol (2.5 mg) alone
Number of subjects: 338
Study: 7878598

Group type: COMPARATOR
Intervention: Single dose of lithium (1.68 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Repetitive doses of lithium (0.56 mg twice a day for 11 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3067180

Group type: EXPERIMENTAL
Intervention: Topically applied tretinoin ophthalmic ointment (0.01%)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 2248069

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 30
Study: 4594581

Group type: EXPERIMENTAL
Intervention: 100 to 1,000 mug GHRIH administered by constant infusion over 75 minutes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 25 mug GHRIH administered by constant infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 10 mug GHRIH administered by constant infusion
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 500 mug GHRIH injected by intravenous, subcutaneous, and intramuscular routes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 500 mug GHRIH injected intramuscularly in 2 ml of 16% gelatin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 4 mg GHRIH in 1 ml of arachis oil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1,000 mug GHRIH during oral 50-g glucose tolerance test
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline during oral 50-g glucose tolerance test
Number of subjects: 8
Study: 31605307

Group type: EXPERIMENTAL
Intervention: Roux-en-Y (RY) group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Billroth I group
Number of subjects: 180

Group type: COMPARATOR
Intervention: Billroth II group
Number of subjects: 180
Study: 28578592

Group type: EXPERIMENTAL
Intervention: Adjunctive minocycline (200 mg/day)
Number of subjects: 71
Study: 25948479

Group type: EXPERIMENTAL
Intervention: internet-based telerehabilitation program in addition to standard cardiac rehabilitation
Number of subjects: 140

Group type: COMPARATOR
Intervention: standard cardiac rehabilitation alone
Number of subjects: 140
Study: 23828329

Group type: EXPERIMENTAL
Intervention: Herbal supplement composed of Curcuma longa and Boswellia serrata
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 21768611

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 98

Group type: COMPARATOR
Intervention: Valproate
Number of subjects: 98
Study: 19493983

Group type: EXPERIMENTAL
Intervention: Communication with parents about sexuality
Number of subjects: 14944

Group type: EXPERIMENTAL
Intervention: Communication with other adult family members about sexuality
Number of subjects: 14944

Group type: EXPERIMENTAL
Intervention: Communication with teachers about sexuality
Number of subjects: 14944

Group type: EXPERIMENTAL
Intervention: Communication with parents in Dar es Salaam
Number of subjects: 14944

Group type: EXPERIMENTAL
Intervention: Communication silence in South African sites
Number of subjects: 14944

Group type: EXPERIMENTAL
Intervention: Socioeconomic status and communication
Number of subjects: 14944

Group type: EXPERIMENTAL
Intervention: Explained variation in communication across sites
Number of subjects: 14944
Study: 17059514

Group type: EXPERIMENTAL
Intervention: Half elemental diet
Number of subjects: 51

Group type: COMPARATOR
Intervention: Free diet
Number of subjects: 51
Study: 15243279

Group type: EXPERIMENTAL
Intervention: tibolone (2.5mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 11349008

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372

Group type: COMPARATOR
Intervention: Genotype CC
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Genotype CT
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Genotype TT
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Genotype TT or CT
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Genotype progression
Number of subjects: 372
Study: 9754458

Group type: EXPERIMENTAL
Intervention: 19 or 21 mm SJM aortic valves (Group 1)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 23 or 25 mm SJM aortic valves (Group 2)
Number of subjects: 88
Study: 7924451

Group type: EXPERIMENTAL
Intervention: Oxiconazole nitrate lotion, 1 percent, used once or twice daily
Number of subjects: 410

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 410
Study: 3122700

Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tranylcypromine sulfate
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clorgiline
Number of subjects: 27
Study: 29737801

Group type: EXPERIMENTAL
Intervention: Self-efficacy education based on the Health Belief Model for 3 months followed by a 24-week follow-up
Number of subjects: 240

Group type: COMPARATOR
Intervention: Conventional dietary counseling
Number of subjects: 240
Study: 27514696

Group type: EXPERIMENTAL
Intervention: Interspinous spacer (ISP) implantation
Number of subjects: 53

Group type: COMPARATOR
Intervention: Decompressive laminectomy (DL)
Number of subjects: 53
Study: 26003434

Group type: EXPERIMENTAL
Intervention: Transdiagnostic Behavior Therapy (TBT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control psychotherapy
Number of subjects: 96
Study: 23410234

Group type: EXPERIMENTAL
Intervention: Guttman-type scale of 'basic mobility'
Number of subjects: 1164

Group type: EXPERIMENTAL
Intervention: Guttman-type scale of 'walking'
Number of subjects: 1164

Group type: EXPERIMENTAL
Intervention: Newly developed scales
Number of subjects: 1164
Study: 20578385

Group type: EXPERIMENTAL
Intervention: Heavy manipulation of acupuncture
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Gentle manipulation of acupuncture
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control therapy (acupuncture or other therapy on the upper extremities)
Number of subjects: 9
Study: 18251359

Group type: EXPERIMENTAL
Intervention: Triptorelin (0.2 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: hCG (5,000 IU)
Number of subjects: 25
Study: 17409969

Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day)
Number of subjects: 342
Study: 14614665

Group type: EXPERIMENTAL
Intervention: Atovaquone and proguanil (20 and 8 mg/kg of body weight, respectively, administered once daily for 3 days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Amodiaquine (10 mg/kg of body weight, once daily for 3 days)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 11590579

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9462194

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: IL-6 and C-reactive protein on day 0, together with either TNF alpha on day 1 or C-reactive protein on day 2
Number of subjects: 68
Study: 7930011

Group type: EXPERIMENTAL
Intervention: Retention sutures
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tensed Silastic-Dacron strips
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 75
Study: 2834931

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Amodiaquine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mefloquine
Number of subjects: 32
Study: 31176480

Group type: EXPERIMENTAL
Intervention: Haraguchi Type II PM ankle fractures
Number of subjects: 73

Group type: COMPARATOR
Intervention: Haraguchi Type III PM ankle fractures
Number of subjects: 73
Study: 28419248

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg intravenously every 2 weeks
Number of subjects: 821

Group type: COMPARATOR
Intervention: Everolimus 10 mg tablet orally once daily
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Nivolumab (Japanese subgroup)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Everolimus (Japanese subgroup)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Nivolumab (Japanese patients)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Everolimus (Japanese patients)
Number of subjects: 821
Study: 26665291

Group type: EXPERIMENTAL
Intervention: O-R power toothbrush (Oral-B Professional Care 1000 with CrossAction brush head)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Sonic toothbrush (Sonicare DiamondClean with standard brush head)
Number of subjects: 148
Study: 23890405

Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine formulations (AS03(A), AS03(B), AS03(C) with varying tocopherol and MPL doses)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: AS03(A)-MPL25, AS03(B)-MPL25, AS03(B)-MPL50
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Adjuvanted seasonal influenza vaccine
Number of subjects: 400

Group type: COMPARATOR
Intervention: Non-adjuvanted vaccine
Number of subjects: 400
Study: 21145181

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard (Std) intake interview
Number of subjects: 75
Study: 19576643

Group type: EXPERIMENTAL
Intervention: Mastitis control plan implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased trial sizes
Number of subjects: 0
Study: 17544886

Group type: EXPERIMENTAL
Intervention: Enoximone (0.35 mg/kg bolus; 0.15 mg/kg before aortic cross-clamping and 0.2 mg/kg in cardioplegic solution)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study: 15209181

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation program (four-week program with one-year follow-up)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Continued care within primary care (control group)
Number of subjects: 236
Study: 11472288

Group type: EXPERIMENTAL
Intervention: Normothermic CPB (>35 degrees C) in diabetic patients (Group DN, n=8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hypothermic CPB (32 degrees C) in diabetic patients (Group DH, n=8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normothermic CPB in age-matched non-diabetic patients (Group CN, n=8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hypothermic CPB in age-matched non-diabetic patients (Group CH, n=8)
Number of subjects: 16
Study: 9813958

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7726876

Group type: COMPARATOR
Intervention: HemoTec
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Hemochron
Number of subjects: 113
Study: 2527401

Group type: EXPERIMENTAL
Intervention: 300 mg clodronate infused intravenously daily for 10 days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 300 mg clodronate dissolved in 500 ml saline for 2 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: 500 ml saline (control) for 2 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral administration of 1200 mg clodronate for 2 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 100 mg clodronate for 2 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with 1200 mg clodronate/day for at least 6 weeks after a 2-week intravenous treatment course
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Routine biochemical examination during and after treatment
Number of subjects: 80
Study: 779056

Group type: EXPERIMENTAL
Intervention: Ulcerone (tripotassium di-citrato bismuthate) for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30579753

Group type: EXPERIMENTAL
Intervention: Selamectin plus sarolaner
Number of subjects: 405

Group type: COMPARATOR
Intervention: Imidacloprid plus moxidectin
Number of subjects: 405
Study: 28287819

Group type: EXPERIMENTAL
Intervention: Breastfeeding Motivation Program (BMP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 26231301

Group type: EXPERIMENTAL
Intervention: Partial caries removal (PCR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Total caries removal (TCR)
Number of subjects: 48
Study: 23436842

Group type: EXPERIMENTAL
Intervention: Organ-based tube current modulation
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Breast shield
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Breast shield plus organ-based tube current modulation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study: 22005142

Group type: EXPERIMENTAL
Intervention: Videoconferencing interviews for medication therapy management (MTM) services
Number of subjects: 43
Study: 19277992

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (22 mg Zn d(‐1) as zinc gluconate)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 17292364

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system
Number of subjects: 0

Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 0